BR112017018620A2 - método de administração de tradipitanto, e, tradipitanto. - Google Patents

método de administração de tradipitanto, e, tradipitanto.

Info

Publication number
BR112017018620A2
BR112017018620A2 BR112017018620-9A BR112017018620A BR112017018620A2 BR 112017018620 A2 BR112017018620 A2 BR 112017018620A2 BR 112017018620 A BR112017018620 A BR 112017018620A BR 112017018620 A2 BR112017018620 A2 BR 112017018620A2
Authority
BR
Brazil
Prior art keywords
tradipitanto
administration
tradipitant
treatment method
application relates
Prior art date
Application number
BR112017018620-9A
Other languages
English (en)
Inventor
H. Polymeropoulos Mihael
William Licamele Louis
Original Assignee
Vanda Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc. filed Critical Vanda Pharmaceuticals Inc.
Publication of BR112017018620A2 publication Critical patent/BR112017018620A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Encapsulation Of And Coatings For Semiconductor Or Solid State Devices (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Eye Examination Apparatus (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

este pedido refere-se a um método de tratamento com tradipitanto e, mais particularmente, a um método de tratamento de prurido com tradipitanto.
BR112017018620-9A 2015-03-04 2016-03-04 método de administração de tradipitanto, e, tradipitanto. BR112017018620A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562128472P 2015-03-04 2015-03-04
US62/128472 2015-03-04
US201562232644P 2015-09-25 2015-09-25
US62/232644 2015-09-25
PCT/US2016/021015 WO2016141341A1 (en) 2015-03-04 2016-03-04 Method of treatment with tradipitant

Publications (1)

Publication Number Publication Date
BR112017018620A2 true BR112017018620A2 (pt) 2018-04-17

Family

ID=55629110

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017018620-9A BR112017018620A2 (pt) 2015-03-04 2016-03-04 método de administração de tradipitanto, e, tradipitanto.

Country Status (20)

Country Link
US (5) US10463655B2 (pt)
EP (2) EP3265087B1 (pt)
JP (4) JP6891385B2 (pt)
KR (2) KR20230173743A (pt)
CN (2) CN107427502B (pt)
AU (3) AU2016226006B2 (pt)
BR (1) BR112017018620A2 (pt)
CA (2) CA2978736C (pt)
CL (1) CL2017002238A1 (pt)
DK (1) DK3265087T3 (pt)
ES (1) ES2824552T3 (pt)
HK (1) HK1248552A1 (pt)
HR (1) HRP20201627T1 (pt)
HU (1) HUE050944T2 (pt)
IL (1) IL254142B (pt)
MX (2) MX2017011279A (pt)
PT (1) PT3265087T (pt)
RU (1) RU2770050C2 (pt)
WO (1) WO2016141341A1 (pt)
ZA (1) ZA201706059B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230173743A (ko) * 2015-03-04 2023-12-27 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피턴트에 의한 치료 방법
JP7347743B2 (ja) * 2017-09-13 2023-09-20 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによるアトピー性皮膚炎の改善された治療
EP3710000A1 (en) * 2017-11-17 2020-09-23 Vanda Pharmaceuticals Inc. Method of treatment of gastrointestinal diseases with tradipitant
JP7410137B2 (ja) * 2018-06-08 2024-01-09 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントを用いる処置方法
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
JP7468964B2 (ja) * 2018-09-28 2024-04-16 バンダ・ファーマシューティカルズ・インコーポレイテッド 動揺病におけるトラジピタントの使用
US20220096449A1 (en) * 2018-12-03 2022-03-31 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
WO2020132513A1 (en) 2018-12-21 2020-06-25 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
AU2021227900A1 (en) 2020-02-25 2022-09-15 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
WO2021195205A1 (en) 2020-03-26 2021-09-30 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
WO2023034718A1 (en) 2021-08-31 2023-03-09 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW263498B (pt) 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
GB9513972D0 (en) 1995-07-08 1995-09-06 Merck Sharp & Dohme Pharmaceutical compositions
PT1394150E (pt) 1999-02-24 2011-02-17 Hoffmann La Roche Derivados de 4-fenilpiridina e a sua utilização como antagonistas dos receptores de nc-1
US6849624B2 (en) 2001-07-31 2005-02-01 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted amides
AR039329A1 (es) * 2002-04-26 2005-02-16 Lilly Co Eli Derivados de triazol, antagonistas de receptor de taquicinina
PT1501808E (pt) 2002-04-26 2008-09-26 Lilly Co Eli Antagonistas de receptores taquiquininas
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
NZ545917A (en) 2003-10-24 2009-11-27 Lilly Co Eli Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
WO2007096782A2 (en) 2006-02-22 2007-08-30 Valorisation Recherche Hscm, Limited Partnership Compositions for disorders associated wtth metachromatic cell activation
RS53386B (en) * 2006-12-20 2014-10-31 Eli Lilly & Company NEW INTERMEDIATE AND PROCESS USED IN PRODUCTION {2- [1- (3,5-BI-TRIFLUOROMETHYL-BENZYL) -5-PYRIDIN-4-IL-1H- [1,2,3] TRIAZOL-4-IL] -PYRIDINE -3-IL} - (2-CHLOROPHENYL) -METHANONE
US20150320866A1 (en) 2012-12-13 2015-11-12 Heron Therapeutics, Inc. Pharmaceutical composition comprising antiemetic compounds and polyorthoester
MX366728B (es) * 2013-06-24 2019-07-22 Menlo Therapeutics Inc Uso de serlopitant como antagonistas del receptor nk-1 en prurito.
US8906951B1 (en) * 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
KR20230173743A (ko) * 2015-03-04 2023-12-27 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피턴트에 의한 치료 방법
JP7347743B2 (ja) * 2017-09-13 2023-09-20 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによるアトピー性皮膚炎の改善された治療
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness

Also Published As

Publication number Publication date
US20220226295A1 (en) 2022-07-21
EP3265087B1 (en) 2020-07-22
CA2978736C (en) 2023-11-07
CN107427502B (zh) 2021-06-04
MX2017011279A (es) 2018-01-25
JP2018507243A (ja) 2018-03-15
PT3265087T (pt) 2020-10-15
HK1248552A1 (zh) 2018-10-19
IL254142A0 (en) 2017-10-31
CN107427502A (zh) 2017-12-01
AU2021202956B2 (en) 2023-06-29
US20200360358A1 (en) 2020-11-19
IL254142B (en) 2022-05-01
US20190290625A1 (en) 2019-09-26
US11324735B2 (en) 2022-05-10
HUE050944T2 (hu) 2021-01-28
CA3213864A1 (en) 2016-09-09
MX2021010460A (es) 2021-09-21
KR20170122777A (ko) 2017-11-06
EP3265087A1 (en) 2018-01-10
ES2824552T3 (es) 2021-05-12
JP2023052486A (ja) 2023-04-11
CN113262221A (zh) 2021-08-17
RU2017134443A (ru) 2019-04-04
AU2016226006B2 (en) 2021-03-04
RU2017134443A3 (pt) 2019-09-05
AU2021202956A1 (en) 2021-06-03
JP2021073258A (ja) 2021-05-13
ZA201706059B (en) 2023-08-30
AU2016226006A1 (en) 2017-09-21
CA2978736A1 (en) 2016-09-09
US20190290626A1 (en) 2019-09-26
JP2024074963A (ja) 2024-05-31
HRP20201627T1 (hr) 2021-02-19
KR20230173743A (ko) 2023-12-27
DK3265087T3 (da) 2020-10-19
RU2770050C2 (ru) 2022-04-14
CL2017002238A1 (es) 2018-04-20
EP3730140A1 (en) 2020-10-28
WO2016141341A1 (en) 2016-09-09
JP6891385B2 (ja) 2021-06-18
US10772880B2 (en) 2020-09-15
AU2023233141A1 (en) 2023-10-12
US20180110761A1 (en) 2018-04-26
US10463655B2 (en) 2019-11-05

Similar Documents

Publication Publication Date Title
BR112017018620A2 (pt) método de administração de tradipitanto, e, tradipitanto.
NZ730809A (en) Methods for treating filoviridae virus infections
EA201890204A1 (ru) Антибактериальные соединения
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
BR112018010211A2 (pt) formulação farmacêutica aquosa compreendendo anticorpo anti-pd-l1 avelumab
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
MX2023006706A (es) Administracion transdermica de agentes grandes en composiciones de emulsion mediante acondicionamiento de la piel con microagujas y sus usos.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
EA201790650A1 (ru) Лекарственная форма и способы применения абиратерона ацетата
EA201600026A1 (ru) Бактериальная гиалуронидаза и способ ее производства
MA40457A (fr) Combinaison de médicaments pour traiter le myélome multiple
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
ZA201703467B (en) Methods of treating ocular conditions
IN2014CH00840A (pt)
EA201792527A1 (ru) Лечение зуда
CL2016000396A1 (es) Tratamiento contra el mieloma múltiple
MX2023009432A (es) Metodo para crear un compuesto a base de mercurio, compuesto a base de mercurio, metodos de uso del compuesto a base de mercurio y usos del compuesto a base de mercurio.
EA201792578A1 (ru) Многослойная сборка
BR112018008181A2 (pt) baclofen intravenoso e métodos de tratamento
PH12016502111A1 (en) Drug for treatment of tinnitus patients
UA104671U (uk) Застосування яктону як нейропротектора
PL413167A1 (pl) Sposób budowy
UA97245U (en) Succinic acid application to strengthen the antihypoxic effect of thiotriazoline and quercetin
UA107862U (uk) Спосіб комплексного лікування хронічного апікального періодонтиту в стадії загострення
TN2014000522A1 (fr) لوح مدرسي بوجهين

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]